Comprehensive Stock Comparison
Compare Organon & Co. (OGN) vs AbbVie Inc. (ABBV) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ABBV | 3.7% revenue growth vs OGN's -2.9% |
| Value | OGN | Lower P/E (2.1x vs 16.0x) |
| Quality / Margins | ABBV | 4.0% net margin vs OGN's 3.0% |
| Stability / Safety | ABBV | Beta 0.42 vs OGN's 0.92 |
| Dividends | ABBV | 2.7% yield; 12-year raise streak; OGN pays no meaningful dividend |
| Momentum (1Y) | ABBV | +14.2% vs OGN's -50.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Organon is a global healthcare company focused on women's health, biosimilars, and established medicines. It generates revenue primarily from its women's health portfolio — including contraceptives and fertility treatments — along with biosimilars and cardiovascular/respiratory drugs, with women's health representing its largest segment. The company's competitive advantage lies in its specialized focus on women's health — a traditionally underserved market — combined with a diversified portfolio of established, off-patent medicines that provide stable cash flow.
AbbVie is a global biopharmaceutical company that develops and markets innovative medicines for serious health conditions. It generates revenue primarily from prescription drug sales — with immunology drugs like Skyrizi and Rinvoq now driving growth as Humira faces biosimilar competition — and also earns income from its aesthetics portfolio including Botox. The company's competitive advantage lies in its deep R&D pipeline, strong patent portfolio, and established commercial infrastructure for launching new blockbuster therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ABBV leads in 4 of 6 categories (Financial Metrics, Total Returns). OGN leads in 2 (Valuation Metrics, Profitability & Efficiency).
Financial Metrics (TTM)
ABBV is the larger business by revenue, generating $59.6B annually — 9.6x OGN's $6.2B. Profitability is closely matched — net margins range from 4.0% (ABBV) to 3.0% (OGN). On growth, ABBV holds the edge at +9.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OGNOrganon & Co. | ABBVAbbVie Inc. |
|---|---|---|
| RevenueTrailing 12 months | $6.2B | $59.6B |
| EBITDAEarnings before interest/tax | $1.6B | $17.3B |
| Net IncomeAfter-tax profit | $187M | $2.4B |
| Free Cash FlowCash after capex | $308M | $20.6B |
| Gross MarginGross profit ÷ Revenue | +53.6% | +69.7% |
| Operating MarginEBIT ÷ Revenue | +20.0% | +15.2% |
| Net MarginNet income ÷ Revenue | +3.0% | +4.0% |
| FCF MarginFCF ÷ Revenue | +5.0% | +34.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -5.3% | +9.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | -88.7% |
Valuation Metrics
At 10.1x trailing earnings, OGN trades at a 90% valuation discount to ABBV's 97.1x P/E. On an enterprise value basis, OGN's 1.2x EV/EBITDA is more attractive than ABBV's 27.0x.
| Metric | OGNOrganon & Co. | ABBVAbbVie Inc. |
|---|---|---|
| Market CapShares × price | $1.9B | $410.1B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $472.4B |
| Trailing P/EPrice ÷ TTM EPS | 10.13x | 97.08x |
| Forward P/EPrice ÷ next-FY EPS est. | 2.09x | 15.95x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 1.16x | 26.96x |
| Price / SalesMarket cap ÷ Revenue | 0.30x | 7.28x |
| Price / BookPrice ÷ Book value/share | 2.10x | 122.29x |
| Price / FCFMarket cap ÷ FCF | — | 23.00x |
Profitability & Efficiency
ABBV delivers a 62.2% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $21 for OGN. On the Piotroski fundamental quality scale (0–9), ABBV scores 6/9 vs OGN's 0/9, reflecting solid financial health.
| Metric | OGNOrganon & Co. | ABBVAbbVie Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +20.6% | +62.2% |
| ROA (TTM)Return on assets | — | +1.8% |
| ROICReturn on invested capital | +19.8% | +11.1% |
| ROCEReturn on capital employed | — | +9.5% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 6 |
| Debt / EquityFinancial leverage | — | 20.17x |
| Net DebtTotal debt minus cash | $0 | $62.3B |
| Cash & Equiv.Liquid assets | — | $5.5B |
| Total DebtShort + long-term debt | $0 | $67.8B |
| Interest CoverageEBIT ÷ Interest expense | 2.36x | 1.58x |
Total Returns (with DRIP)
A $10,000 investment in ABBV five years ago would be worth $24,166 today (with dividends reinvested), compared to $3,480 for OGN. Over the past 12 months, ABBV leads with a +14.2% total return vs OGN's -50.6%. The 3-year compound annual growth rate (CAGR) favors ABBV at 17.7% vs OGN's -26.8% — a key indicator of consistent wealth creation.
| Metric | OGNOrganon & Co. | ABBVAbbVie Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +1.0% | +1.9% |
| 1-Year ReturnPast 12 months | -50.6% | +14.2% |
| 3-Year ReturnCumulative with dividends | -60.8% | +63.1% |
| 5-Year ReturnCumulative with dividends | -65.2% | +141.7% |
| 10-Year ReturnCumulative with dividends | -65.2% | +413.0% |
| CAGR (3Y)Annualised 3-year return | -26.8% | +17.7% |
Risk & Volatility
ABBV is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than OGN's 0.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABBV currently trades 94.8% from its 52-week high vs OGN's 45.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OGNOrganon & Co. | ABBVAbbVie Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.92x | 0.42x |
| 52-Week HighHighest price in past year | $16.08 | $244.81 |
| 52-Week LowLowest price in past year | $6.18 | $164.39 |
| % of 52W HighCurrent price vs 52-week peak | +45.3% | +94.8% |
| RSI (14)Momentum oscillator 0–100 | 39.2 | 49.6 |
| Avg Volume (50D)Average daily shares traded | 4.8M | 5.7M |
Analyst Outlook
Wall Street rates OGN as "Buy" and ABBV as "Buy". Consensus price targets imply 10.4% upside for ABBV (target: $256) vs -10.8% for OGN (target: $7). ABBV is the only dividend payer here at 2.68% yield — a key consideration for income-focused portfolios.
| Metric | OGNOrganon & Co. | ABBVAbbVie Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.50 | $256.15 |
| # AnalystsCovering analysts | 8 | 39 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% |
| Dividend StreakConsecutive years of raises | 0 | 12 |
| Dividend / ShareAnnual DPS | — | $6.22 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| Organon & Co. (OGN) | 100 | 24.66 | -75.3% |
| AbbVie Inc. (ABBV) | 100 | 201.09 | +101.1% |
AbbVie Inc. (ABBV) returned +142% over 5 years vs Organon & Co. (OGN)'s -65%. A $10,000 investment in ABBV 5 years ago would be worth $24,166 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Organon & Co. (OGN) | $9.8B | $6.2B | -36.4% |
| AbbVie Inc. (ABBV) | $25.6B | $56.3B | +119.7% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Organon & Co. (OGN) | 22.0% | 3.0% | -86.3% |
| AbbVie Inc. (ABBV) | 23.2% | 7.6% | -67.3% |
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Organon & Co. (OGN) | 5.7 | 10 | +75.4% |
| AbbVie Inc. (ABBV) | 29.3 | 74.4 | +153.9% |
Organon & Co. has traded in a 4x–10x P/E range over 5 years; current trailing P/E is ~10x. AbbVie Inc. has traded in a 17x–74x P/E range over 8 years; current trailing P/E is ~97x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Organon & Co. (OGN) | 8.51 | 0.72 | -91.5% |
| AbbVie Inc. (ABBV) | 3.63 | 2.39 | -34.2% |
Chart 6Free Cash Flow — 5 Years
Organon & Co. generated $0M FCF in 2025 (-100% vs 2021). AbbVie Inc. generated $18B FCF in 2024 (-19% vs 2021).
OGN vs ABBV: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is OGN or ABBV a better buy right now?
Organon & Co. (OGN) offers the better valuation at 10.1x trailing P/E (2.1x forward), making it the more compelling value choice. Analysts rate Organon & Co. (OGN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OGN or ABBV?
On trailing P/E, Organon & Co. (OGN) is the cheapest at 10.1x versus AbbVie Inc. at 97.1x. On forward P/E, Organon & Co. is actually cheaper at 2.1x.
03Which is the better long-term investment — OGN or ABBV?
Over the past 5 years, AbbVie Inc. (ABBV) delivered a total return of +141.7%, compared to -65.2% for Organon & Co. (OGN). A $10,000 investment in ABBV five years ago would be worth approximately $24K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ABBV returned +413.0% versus OGN's -65.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OGN or ABBV?
By beta (market sensitivity over 5 years), AbbVie Inc. (ABBV) is the lower-risk stock at 0.42β versus Organon & Co.'s 0.92β — meaning OGN is approximately 117% more volatile than ABBV relative to the S&P 500.
05Which has better profit margins — OGN or ABBV?
AbbVie Inc. (ABBV) is the more profitable company, earning 7.6% net margin versus 3.0% for Organon & Co. — meaning it keeps 7.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OGN leads at 20.7% versus 16.2% for ABBV. At the gross margin level — before operating expenses — ABBV leads at 70.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OGN or ABBV more undervalued right now?
On forward earnings alone, Organon & Co. (OGN) trades at 2.1x forward P/E versus 16.0x for AbbVie Inc. — 13.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 10.4% to $256.15.
07Which pays a better dividend — OGN or ABBV?
In this comparison, ABBV (2.7% yield) pays a dividend. OGN does not pay a meaningful dividend and should not be held primarily for income.
08Is OGN or ABBV better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc. (ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.42), 2.7% yield, +413.0% 10Y return). Both have compounded well over 10 years (ABBV: +413.0%, OGN: -65.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OGN and ABBV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OGN is a small-cap deep-value stock; ABBV is a large-cap quality compounder stock. ABBV pays a dividend while OGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.